D. Ross Camidge
Led the crizotinib and brigatinib trials that defined ALK-targeted lung cancer therapy.
Overview
Ross Camidge led the first crizotinib expansion cohort in ALK-positive lung cancer and was principal investigator of the ALTA and ALTA-1L brigatinib trials, and senior author on ALEX (alectinib). He has championed CNS-specific endpoints and ctDNA monitoring in oncogene-driven disease. He directs thoracic oncology research at the University of Colorado.
Pages like this
not linked directly; found by shared links- PersonBenjamin Solomon
Shares CROWN, CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer, Lorlatinib, ALK.
- PersonMyung-Ju Ahn
Shares CROWN, Lorlatinib, ALK, Non-small-cell lung cancer and the tag lung.
- PersonYael P. Mossé
Shares Lorlatinib, ALK, Small-molecule kinase inhibitors and the tag alk.
- PersonDong-Wan Kim
Shares CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer, Lorlatinib, ALK, Non-small-cell lung cancer.
- PersonFerdinandos Skoulidis
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
- PairingSequence: targeted therapy before immunotherapy in driver-positive NSCLC
Shares CROWN, Lorlatinib, ALK, Small-molecule kinase inhibitors.
- ProductBrigatinib
Shares ALK, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
- ProductNeladalkib
Shares Lorlatinib, ALK, Small-molecule kinase inhibitors, Non-small-cell lung cancer.